StemCells, R Biomedical unite to develop iPS cell lines and reagents

11/2/2012 | Genetic Engineering & Biotechnology News

R Biomedical and StemCells agreed to jointly develop cell lines and reagents for use in human induced pluripotent stem cell studies aimed at regenerative medicine. The partners said they have commercialized their first product together, an "ultra-primary" human fibroblast cell line designed for iPS cell generation.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR